Argenx SE announced it achieved an overall response rate of 92% in patients with AML with its anti-TNFSF7 (CD70) antibody cusatuzumab.
Sanofi has acquired the global commercialisation rights for two preclinical programmes from Denali Therapeutics.
Dutch ProQR NV has licensed global commercialisation rights to IONIS-RHO-2.5Rx (QR-1123) from Ionis Pharmaceuticals, to treat autosomal dominant retinitis pigmentosa (adRP)
The EIB has agreed to support Italian CNS drug developer Newron Pharmaceuticals with up to €40m to support the development of the company’s late-stage pipeline.
TES Pharma has presented a novel treatment approach for acute kidney injury and non-alcoholic fatty liver disease in Nature.
The European Parliament has approved measures that could lead to a ban of the top 10 single use plastic products that contribute to marine littering by 2021.
AstraZeneca plc has extended its immunoncology pipeline by an extension of its partnership with French Innate Pharma SA.
French Enterome SA has added a second licence agreement with Takeda to its deal portfolio, projecting possible payments of US$640m.
The European Medicines Agency delays the EU approval of Nivolumab/Ipilimumab in NSCLC and greenlights four biotherapeutics to be marketed in the EU.
Industrial biotech innovations, presented in at the 11th EFIB in Toulouse, could become the key enabler set to save our planet if supported appropriately.